This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

How Far Have We Come?

R. J. Simonds, MD; Martha Rogers, MD

JAMA. 1996;275(19):1514-1515.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

During the past 2 decades, perinatal transmission of human immunodeficiency virus (HIV) has become a major cause of illness and death among children in the United States, having infected more than 15 000 children and having claimed more than 3000 lives.¹ An important turning point in this epidemic occurred on February 21,1994, when the National Institutes of Health (NIH) announced the interim results of AIDS Clinical Trials Group (ACTG) Protocol 076, which demonstrated that zidovudine administered to a group of HIV-infected women during pregnancy and labor and to their newborns reduced the risk for perinatal HIV transmission by two thirds.² This dramatic prevention breakthrough offered both the hope of substantially controlling the HIV epidemic in children and the challenge of turning this hope into reality. In response to this challenge, a multifaceted campaign was launched by public and private health organizations, community groups, and individuals to translate the . . . [Full Text PDF of this Article]

Author Affiliations
From the Epidemiology Branch, Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Ga.

Footnotes
Corresponding author: R. J. Simonds, MD, Epidemiology Branch, DHAP, NCHSTP, Mailstop E-45, Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?